147 related articles for article (PubMed ID: 30107886)
1. Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
Connor EV; Newlin EM; Jelovsek JE; AlHilli MM
Gynecol Oncol; 2018 Oct; 151(1):129-133. PubMed ID: 30107886
[TBL] [Abstract][Full Text] [Related]
2. Risk-scoring model for prediction of non-home discharge in epithelial ovarian cancer patients.
AlHilli MM; Tran CW; Langstraat CL; Martin JR; Weaver AL; McGree ME; Mariani A; Cliby WA; Bakkum-Gamez JN
J Am Coll Surg; 2013 Sep; 217(3):507-15. PubMed ID: 23816386
[TBL] [Abstract][Full Text] [Related]
3. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
Ross MS; Burriss ME; Winger DG; Edwards RP; Courtney-Brooks M; Boisen MM
Gynecol Oncol; 2018 Aug; 150(2):306-310. PubMed ID: 29929924
[TBL] [Abstract][Full Text] [Related]
4. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
Barlin JN; Yu C; Hill EK; Zivanovic O; Kolev V; Levine DA; Sonoda Y; Abu-Rustum NR; Huh J; Barakat RR; Kattan MW; Chi DS
Gynecol Oncol; 2012 Apr; 125(1):25-30. PubMed ID: 22155261
[TBL] [Abstract][Full Text] [Related]
5. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
[TBL] [Abstract][Full Text] [Related]
6. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
8. A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
Chesnais M; Lecuru F; Mimouni M; Ngo C; Fauconnier A; Huchon C
PLoS One; 2017; 12(11):e0187245. PubMed ID: 29117194
[TBL] [Abstract][Full Text] [Related]
9. Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer.
Rutten MJ; Boldingh JH; Schuit E; Trum H; van Driel W; Mol BW; Kenter GG; Buist MR
Gynecol Oncol; 2014 Oct; 135(1):13-8. PubMed ID: 25093289
[TBL] [Abstract][Full Text] [Related]
10. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
[TBL] [Abstract][Full Text] [Related]
11. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
[TBL] [Abstract][Full Text] [Related]
12. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
14. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
15. Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma.
Clark RM; Growdon WB; Wiechert A; Boruta D; Del Carmen M; Goodman AK; Bradford L; Rauh-Hain A; Schorge JO
Gynecol Oncol; 2013 Sep; 130(3):407-10. PubMed ID: 23747329
[TBL] [Abstract][Full Text] [Related]
16. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
Pepin K; Bregar A; Davis M; Melamed A; Hinchcliff E; Gockley A; Horowitz N; Del Carmen MG
Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028
[TBL] [Abstract][Full Text] [Related]
17. Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
Uccella S; Mele MC; Quagliozzi L; Rinninella E; Nero C; Cappuccio S; Cintoni M; Gasbarrini A; Scambia G; Fagotti A
Gynecol Oncol; 2018 May; 149(2):263-269. PubMed ID: 29550182
[TBL] [Abstract][Full Text] [Related]
18. Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer.
Nieuwenhuyzen-de Boer GM; Gerestein CG; Eijkemans MJ; Burger CW; Kooi GS
Eur J Gynaecol Oncol; 2016; 37(1):63-8. PubMed ID: 27048112
[TBL] [Abstract][Full Text] [Related]
19. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.
Frederick PJ; Ramirez PT; McQuinn L; Milam MR; Weber DM; Coleman RL; Gershenson DM; Landen CN
Int J Gynecol Cancer; 2011 Jul; 21(5):831-6. PubMed ID: 21613957
[TBL] [Abstract][Full Text] [Related]
20. Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.
Fotopoulou C; Jones BP; Savvatis K; Campbell J; Kyrgiou M; Farthing A; Brett S; Roux R; Hall M; Rustin G; Gabra H; Jiao L; Stümpfle R
Arch Gynecol Obstet; 2016 Sep; 294(3):607-14. PubMed ID: 27040418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
